Affiliations: [a] Veterans Affairs Puget Sound Health Care System, Seattle, WA, USA
| [b] Department of Medicine, University of Washington, Seattle, WA, USA
| [c] Department of Environmental and Occupational Health Sciences, University of Washington, Seattle, WA, USA
| [d] Department of Internal Medicine, Saint Louis School of Medicine, St. Louis, MO, USA
Correspondence:
[*]
Correspondence to: Elizabeth M. Rhea, Veterans Affairs Puget Sound Health Care System, 1660 S. Columbian Way, Seattle, WA 98108, USA. E-mail: meredime@uw.edu.
Abstract: Research on intranasal delivery of drugs, peptides, and proteins has grown over the past decade as an alternate way to deliver substrates to the brain. Recent work has shown intranasal (INL) delivery of insulin improves memory and cognition in healthy subjects as well as patients with Alzheimer’s disease (AD) and in AD mouse models. However, the molecular mechanism(s) for the beneficial effect of insulin on memory are still unclear. Using the SAMP8 mouse model of AD, we investigated the impact of INL insulin on protein and gene expression in brain regions including the olfactory bulb, hypothalamus, and hippocampus. We found genes and proteins in the insulin receptor signaling pathway were not activated by the doses tested. However, we did find the expression of genes present in the hippocampus involved in other pathways, especially those related to inflammation, were altered due to age and with a dose of INL insulin previously shown to improve cognition. These alternate pathways could be targets of insulin when delivered via the INL route to aid in memory improvement.
